Date: 2014-05-07
Type of information: Distribution agreement
Compound: Arcoxia® (etoricoxib)
Company: Grunenthal (Germany) Merck&Co (USA - NJ)
Therapeutic area: Autoimmune diseases – CNS diseases - Inflammatory diseases - Rheumatic diseases
Type agreement: distribution
Action mechanism: cyclooxygenase-2 inhibitor/COX2 inhibitor
Disease: symptomatic relief of osteoarthritis, rheumatoid arthritis, pain and signs of inflammation associated with acute gouty arthritis
Details: * On May 7th 2014, Grünenthal Group announced the signing of an exclusive promotion and distribution agreement with MSD covering etoricoxib. This agreement covers Germany, UK, France, Belgium, Luxemburg, Ireland, and Austria. Etoricoxib is a patent-protected, selective COX-2 inhibitor, marketed under the brand name Arcoxia® in these markets.
Financial terms:
Latest news:
